Phase II evaluation of amonafide in renal cell carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1991-11

AUTHORS

Celestia S. Higano, Phyllis Goodman, John B. Craig, Julie A. Kish, Saul E. Rivkin, Michael Wolf, E. David Crawford

ABSTRACT

Twenty four patients with advanced renal cell carcinoma were treated in a phase II trial with amonafide 300-450 mg/m2/day on days 1-5 every 21 days. There were no responders, 6 patients had stable disease, 14 experienced progressive disease and 4 were assumed to be non-responders as no evaluation was performed. There were no fatal toxicities although 8 patients had grade 3 or 4 granulocytopenia, 1 patient had grade 4 thrombocytopenia. Other toxicities included grade 3 diarrhea in 1 patient, grade 3 myopathy in 1 patient, severe nausea and vomiting in 1 patient and a facial rash, possibly a hypersensitivity reaction, in 1 patient. The median survival is 7.5 months. At this dosage and schedule, there is no evidence that amonafide has meaningful anti-tumor activity in patients with advanced renal cell carcinoma. More... »

PAGES

361-363

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00183582

DOI

http://dx.doi.org/10.1007/bf00183582

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050095698

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1804814


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isoquinolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Naphthalimides", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Puget Sound", 
          "id": "https://www.grid.ac/institutes/grid.267047.0", 
          "name": [
            "Puget Sound Oncology Consortium, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Higano", 
        "givenName": "Celestia S.", 
        "id": "sg:person.015301615277.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015301615277.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Southwest Oncology Group Statistical Center, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goodman", 
        "givenName": "Phyllis", 
        "id": "sg:person.01167715306.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167715306.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Schumpert Medical Center, Shreveport, LA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Craig", 
        "givenName": "John B.", 
        "id": "sg:person.016547665702.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016547665702.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wayne State University", 
          "id": "https://www.grid.ac/institutes/grid.254444.7", 
          "name": [
            "Wayne State University, Detroit, MI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kish", 
        "givenName": "Julie A.", 
        "id": "sg:person.01172675531.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172675531.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Puget Sound", 
          "id": "https://www.grid.ac/institutes/grid.267047.0", 
          "name": [
            "Puget Sound Oncology Consortium, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rivkin", 
        "givenName": "Saul E.", 
        "id": "sg:person.01114132732.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114132732.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Southwest Oncology Group Statistical Center, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolf", 
        "givenName": "Michael", 
        "id": "sg:person.01225644344.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225644344.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Colorado Denver", 
          "id": "https://www.grid.ac/institutes/grid.241116.1", 
          "name": [
            "University of Colorado, Denver, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crawford", 
        "givenName": "E. David", 
        "id": "sg:person.01261331436.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261331436.43"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00255461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028001825", 
          "https://doi.org/10.1007/bf00255461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00255461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028001825", 
          "https://doi.org/10.1007/bf00255461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/nar/7.1.217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046469620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079513354", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079899120", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1991-11", 
    "datePublishedReg": "1991-11-01", 
    "description": "Twenty four patients with advanced renal cell carcinoma were treated in a phase II trial with amonafide 300-450 mg/m2/day on days 1-5 every 21 days. There were no responders, 6 patients had stable disease, 14 experienced progressive disease and 4 were assumed to be non-responders as no evaluation was performed. There were no fatal toxicities although 8 patients had grade 3 or 4 granulocytopenia, 1 patient had grade 4 thrombocytopenia. Other toxicities included grade 3 diarrhea in 1 patient, grade 3 myopathy in 1 patient, severe nausea and vomiting in 1 patient and a facial rash, possibly a hypersensitivity reaction, in 1 patient. The median survival is 7.5 months. At this dosage and schedule, there is no evidence that amonafide has meaningful anti-tumor activity in patients with advanced renal cell carcinoma.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00183582", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2693226", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693265", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693495", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "name": "Phase II evaluation of amonafide in renal cell carcinoma", 
    "pagination": "361-363", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00183582"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "eea40706c06c81f91c63a4ad5c114666223345195a79ddb848476f870b711817"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050095698"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1804814"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00183582", 
      "https://app.dimensions.ai/details/publication/pub.1050095698"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T08:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91432_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00183582"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00183582'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00183582'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00183582'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00183582'


 

This table displays all metadata directly associated to this object as RDF triples.

191 TRIPLES      21 PREDICATES      46 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00183582 schema:about N06ac92146ad244e7a3bb6042ea68570d
2 N0a54f65fb35d40208218d4c395bac429
3 N0bf2bfbc8a47402b85359393d469084a
4 N15f123777ece4573b93708c02dbd874a
5 N38b63416beb4429d86a08616d06ff477
6 N4301541b88dd4ea6bd75dba669e1ba0c
7 N870cfa3d8bf348009ba50101159b927a
8 Na07c221ae0354508bf177389e51e89dd
9 Na8756db9cd9943dba185287a8b216c1f
10 Nbd51bc6fee7745fbb7f0312a638394c1
11 Nc272a43225b54ccb90022d817b8f8d3f
12 Nc903d1e6f0754eb4a154d4de67a875d5
13 Nfe81201202df4e85a9bd01a207a4a20d
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author Na71bcac3876f467796b8029351330ff5
17 schema:citation sg:pub.10.1007/bf00255461
18 https://app.dimensions.ai/details/publication/pub.1079513354
19 https://app.dimensions.ai/details/publication/pub.1079899120
20 https://doi.org/10.1093/nar/7.1.217
21 schema:datePublished 1991-11
22 schema:datePublishedReg 1991-11-01
23 schema:description Twenty four patients with advanced renal cell carcinoma were treated in a phase II trial with amonafide 300-450 mg/m2/day on days 1-5 every 21 days. There were no responders, 6 patients had stable disease, 14 experienced progressive disease and 4 were assumed to be non-responders as no evaluation was performed. There were no fatal toxicities although 8 patients had grade 3 or 4 granulocytopenia, 1 patient had grade 4 thrombocytopenia. Other toxicities included grade 3 diarrhea in 1 patient, grade 3 myopathy in 1 patient, severe nausea and vomiting in 1 patient and a facial rash, possibly a hypersensitivity reaction, in 1 patient. The median survival is 7.5 months. At this dosage and schedule, there is no evidence that amonafide has meaningful anti-tumor activity in patients with advanced renal cell carcinoma.
24 schema:genre research_article
25 schema:inLanguage en
26 schema:isAccessibleForFree false
27 schema:isPartOf N35fe75abb36a4893b6b88a261bc7bfc6
28 N76ad708ab5e94971adfdf810fe9fe5fc
29 sg:journal.1094201
30 schema:name Phase II evaluation of amonafide in renal cell carcinoma
31 schema:pagination 361-363
32 schema:productId N180e57619173464aba02e7beea017789
33 N2657fafd00a144f1ab80ad1586985a33
34 N3830808753814bcda1d9a2335aaaac0f
35 N81af242d61ba4c5296204535b22ef53a
36 Ne2755b60fe6c4860b2640989d422e1cb
37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050095698
38 https://doi.org/10.1007/bf00183582
39 schema:sdDatePublished 2019-04-15T08:59
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher N3cd1e55e9a4a4aea87e9a6deec062c37
42 schema:url http://link.springer.com/10.1007/BF00183582
43 sgo:license sg:explorer/license/
44 sgo:sdDataset articles
45 rdf:type schema:ScholarlyArticle
46 N06ac92146ad244e7a3bb6042ea68570d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
47 schema:name Middle Aged
48 rdf:type schema:DefinedTerm
49 N0a54f65fb35d40208218d4c395bac429 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
50 schema:name Male
51 rdf:type schema:DefinedTerm
52 N0bf2bfbc8a47402b85359393d469084a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
53 schema:name Aged
54 rdf:type schema:DefinedTerm
55 N15f123777ece4573b93708c02dbd874a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
56 schema:name Aged, 80 and over
57 rdf:type schema:DefinedTerm
58 N180e57619173464aba02e7beea017789 schema:name pubmed_id
59 schema:value 1804814
60 rdf:type schema:PropertyValue
61 N2657fafd00a144f1ab80ad1586985a33 schema:name readcube_id
62 schema:value eea40706c06c81f91c63a4ad5c114666223345195a79ddb848476f870b711817
63 rdf:type schema:PropertyValue
64 N35fe75abb36a4893b6b88a261bc7bfc6 schema:issueNumber 4
65 rdf:type schema:PublicationIssue
66 N3830808753814bcda1d9a2335aaaac0f schema:name doi
67 schema:value 10.1007/bf00183582
68 rdf:type schema:PropertyValue
69 N38b63416beb4429d86a08616d06ff477 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Female
71 rdf:type schema:DefinedTerm
72 N3cd1e55e9a4a4aea87e9a6deec062c37 schema:name Springer Nature - SN SciGraph project
73 rdf:type schema:Organization
74 N4301541b88dd4ea6bd75dba669e1ba0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Carcinoma, Renal Cell
76 rdf:type schema:DefinedTerm
77 N55e7f720d8154e83a8f672f3d149b9ac rdf:first sg:person.01261331436.43
78 rdf:rest rdf:nil
79 N6d39def8090b49898b3cfab96ca69738 rdf:first sg:person.01172675531.33
80 rdf:rest N96a292ba6822495e80bdfc4061c3c3e3
81 N76ad708ab5e94971adfdf810fe9fe5fc schema:volumeNumber 9
82 rdf:type schema:PublicationVolume
83 N81af242d61ba4c5296204535b22ef53a schema:name nlm_unique_id
84 schema:value 8309330
85 rdf:type schema:PropertyValue
86 N870cfa3d8bf348009ba50101159b927a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Antineoplastic Agents
88 rdf:type schema:DefinedTerm
89 N96a292ba6822495e80bdfc4061c3c3e3 rdf:first sg:person.01114132732.78
90 rdf:rest Nb863d92652a547bd97213db79bad0651
91 Na07c221ae0354508bf177389e51e89dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Kidney Neoplasms
93 rdf:type schema:DefinedTerm
94 Na71bcac3876f467796b8029351330ff5 rdf:first sg:person.015301615277.47
95 rdf:rest Ndb56d645ed4c4460b1b493a3bfd07520
96 Na8756db9cd9943dba185287a8b216c1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Humans
98 rdf:type schema:DefinedTerm
99 Nb863d92652a547bd97213db79bad0651 rdf:first sg:person.01225644344.61
100 rdf:rest N55e7f720d8154e83a8f672f3d149b9ac
101 Nbd51bc6fee7745fbb7f0312a638394c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Isoquinolines
103 rdf:type schema:DefinedTerm
104 Nbe34f8996a23470f994f4da9dae5ae25 schema:name Schumpert Medical Center, Shreveport, LA, USA
105 rdf:type schema:Organization
106 Nc272a43225b54ccb90022d817b8f8d3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Drug Evaluation
108 rdf:type schema:DefinedTerm
109 Nc903d1e6f0754eb4a154d4de67a875d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Naphthalimides
111 rdf:type schema:DefinedTerm
112 Ndb56d645ed4c4460b1b493a3bfd07520 rdf:first sg:person.01167715306.61
113 rdf:rest Nea3b436d5d394610a677ab61e34f2ac6
114 Ne2755b60fe6c4860b2640989d422e1cb schema:name dimensions_id
115 schema:value pub.1050095698
116 rdf:type schema:PropertyValue
117 Nea3b436d5d394610a677ab61e34f2ac6 rdf:first sg:person.016547665702.13
118 rdf:rest N6d39def8090b49898b3cfab96ca69738
119 Nfe81201202df4e85a9bd01a207a4a20d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Imides
121 rdf:type schema:DefinedTerm
122 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
123 schema:name Medical and Health Sciences
124 rdf:type schema:DefinedTerm
125 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
126 schema:name Oncology and Carcinogenesis
127 rdf:type schema:DefinedTerm
128 sg:grant.2693226 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00183582
129 rdf:type schema:MonetaryGrant
130 sg:grant.2693265 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00183582
131 rdf:type schema:MonetaryGrant
132 sg:grant.2693495 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00183582
133 rdf:type schema:MonetaryGrant
134 sg:journal.1094201 schema:issn 0167-6997
135 1573-0646
136 schema:name Investigational New Drugs
137 rdf:type schema:Periodical
138 sg:person.01114132732.78 schema:affiliation https://www.grid.ac/institutes/grid.267047.0
139 schema:familyName Rivkin
140 schema:givenName Saul E.
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114132732.78
142 rdf:type schema:Person
143 sg:person.01167715306.61 schema:affiliation https://www.grid.ac/institutes/grid.48336.3a
144 schema:familyName Goodman
145 schema:givenName Phyllis
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167715306.61
147 rdf:type schema:Person
148 sg:person.01172675531.33 schema:affiliation https://www.grid.ac/institutes/grid.254444.7
149 schema:familyName Kish
150 schema:givenName Julie A.
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172675531.33
152 rdf:type schema:Person
153 sg:person.01225644344.61 schema:affiliation https://www.grid.ac/institutes/grid.48336.3a
154 schema:familyName Wolf
155 schema:givenName Michael
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225644344.61
157 rdf:type schema:Person
158 sg:person.01261331436.43 schema:affiliation https://www.grid.ac/institutes/grid.241116.1
159 schema:familyName Crawford
160 schema:givenName E. David
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261331436.43
162 rdf:type schema:Person
163 sg:person.015301615277.47 schema:affiliation https://www.grid.ac/institutes/grid.267047.0
164 schema:familyName Higano
165 schema:givenName Celestia S.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015301615277.47
167 rdf:type schema:Person
168 sg:person.016547665702.13 schema:affiliation Nbe34f8996a23470f994f4da9dae5ae25
169 schema:familyName Craig
170 schema:givenName John B.
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016547665702.13
172 rdf:type schema:Person
173 sg:pub.10.1007/bf00255461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028001825
174 https://doi.org/10.1007/bf00255461
175 rdf:type schema:CreativeWork
176 https://app.dimensions.ai/details/publication/pub.1079513354 schema:CreativeWork
177 https://app.dimensions.ai/details/publication/pub.1079899120 schema:CreativeWork
178 https://doi.org/10.1093/nar/7.1.217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046469620
179 rdf:type schema:CreativeWork
180 https://www.grid.ac/institutes/grid.241116.1 schema:alternateName University of Colorado Denver
181 schema:name University of Colorado, Denver, CO, USA
182 rdf:type schema:Organization
183 https://www.grid.ac/institutes/grid.254444.7 schema:alternateName Wayne State University
184 schema:name Wayne State University, Detroit, MI, USA
185 rdf:type schema:Organization
186 https://www.grid.ac/institutes/grid.267047.0 schema:alternateName University of Puget Sound
187 schema:name Puget Sound Oncology Consortium, Seattle, WA, USA
188 rdf:type schema:Organization
189 https://www.grid.ac/institutes/grid.48336.3a schema:alternateName National Cancer Institute
190 schema:name Southwest Oncology Group Statistical Center, Seattle, WA, USA
191 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...